TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02164071

Intervention type: OTHER
Intervention: Geriatric Assessment of Health Status Scale administration
Description: Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days

Intervention type: OTHER
Intervention: Geriatric Assessment of Health Status Scale administration
Description: Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days

Intervention type: OTHER
Intervention: Geriatric Assessment of Health Status Scale administration
Description: Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
Study: NCT04272047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee Control+ program
Description: 15-20 minute training program to be performed at all team training sessions during the season.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor strengthening program
Description: Adductor strengthening program to be performed 2-3 times per week, one set per side, during the pre-season, and 1 time per week, one set per side during the in-season.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee Control program
Description: 15-20 minute training program to be performed as per the team's usual routines (no intervention from the researchers).
Study: NCT03718234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous hydrocortisone
Description: Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard glucocorticoid therapy
Description: Subjects in this arm will continue on standard oral hydrocortisone therapy
Study: NCT04184011

Intervention type: DEVICE
Intervention: SRT-100™
Description: SRT delivers a precise, calibrated dose of radiotherapy following surgical excision for large and more difficult-to-treat keloids that cannot otherwise be treated by or have failed more conservative measures.
Study: NCT01491841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine + Rituximab + Pixantrone
Description: Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine + Rituximab + Pixantrone
Description: Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine + Rituximab + Pixantrone
Description: Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg administered on Day 2 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg administered on Day 2 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: 6mg administered on Day 2 of each 21 day cycle
Study: NCT01090050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan/Naproxen Sodium
Description: Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
Study: NCT02871284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT00845936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg bid
Study: NCT03539484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7172508
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7172508
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7172508
Description: RO7172508 was administered at a dose and as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab was administered if required, for the management of severe CRS (cytokine release syndrome)
Study: NCT01443923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon-alfa 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon-alfa 2B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT03754972

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sagittal plane shear index (SPSI)
Description: Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
Study: NCT04105842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfilcon A
Description: Participants wear delafilcon A contact lenses on a daily disposable basis.
Study: NCT02983461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, 20mg x 3 times a day for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet, 3 times a day for 10 weeks
Study: NCT00264290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: 900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo designed to resemble Valganciclovir
Study: NCT03403881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity promotion + TAU
Description: Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Weekly call on general health aspects + treatment as usual
Study: NCT02547909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: probe-based Confocal Laser Endomicroscopy
Description: Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellvizio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein 10%
Study: NCT02477436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~* Investigational products were administered prior to the sexual intercourse for total 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~* Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~* Placebos were administered prior to the sexual intercourse for total 8 weeks.
Study: NCT01065571

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carrageenan
Description: The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary intervention with no-carrageenan diet
Description: The intervention will consist of the no-carrageenan diet.
Study: NCT02777424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C \& S

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Pooled collection of plasma from donors
Study: NCT01443923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT02383251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
Study: NCT03035669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness group
Description: 8 week program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading group
Description: 8 week program
Study: NCT01082237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
Study: NCT01079910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isopropylmethylphenol and Fluoride
Description: 0.1% isopropylmethylphenol and 1150ppm fluoride

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride and Silica
Description: NaF/Silica toothpaste containing 1150ppm fluoride
Study: NCT02814383

Intervention type: OTHER
Intervention: Brain Monitoring Platform
Description: This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
Study: NCT03200977

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02749110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling brush
Description: Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
Study: NCT00203268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroergotamine mesylate
Description: 1.0 mg. intramuscularly
Study: NCT01655303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Study: NCT02255071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure wristband
Description: A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham wristband
Description: A wristband over wrist but no acupressure for seven days.
Study: NCT00612651

Intervention type: DRUG
Group type: OTHER
Intervention: Temodar and SCH 66336
Description: 2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Temodar and SCH 66336
Description: 2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated \& escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle \& escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning \& evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 \& 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
Study: NCT00328575

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT)
Description: The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing.
Study: NCT02683408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diosmiplex
Description: diosmiplex is an FDA regulated medical food product
Study: NCT02429102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02704650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid sample
Description: taking a vaginal fluid sample

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluid sample
Description: taking a vaginal fluid sample
Study: NCT02784288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck Dissection
Description: All patients will undergo neck dissection of the cervical lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard-of-Care (SOC) Transoral Surgery of Primary Site
Description: Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SOC Radiation
Description: Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Carboplatin
Description: Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC Paclitaxel
Description: Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
Study: NCT05803681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacitive Coupled Electric Fields (CCEF)
Description: In the CCEF Group, patients received, as an adjunct to the clinical study protocol, CCEF stimulation (Osteospine®, IGEA SpA, Carpi, Italy) 8 h/die for sixty days.

Intervention type: OTHER
Group type: OTHER
Intervention: Calssic clinical protocol
Description: (1) bed rest for the first twenty-five days and subsequent mobilization with a three-point hyperextension brace; (2) antiresorptive therapy (75 mg risedronate tablet weekly); (3) supplemental calcium carbonate with 1000 mg of elemental calcium daily if needed based on serum calcium concentration; (4) Vitamin D (≤500 IU daily) if the serum 25-hydroxyvitamin D concentration at the time of screening was below 16 ng/ml). Analgesic therapy with paracetamol 1000mg tablets was assumed for seven days and further depending on pain intensity; patients were required to report on a specific sheet paracetamol assumption.
Study: NCT02544165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine intake
Description: The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette smoking
Description: The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette smoking
Description: The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine intake and Cigarette smoking
Description: The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
Study: NCT02514551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV
Study: NCT02786472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Bystander Training
Description: Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Substance Abuse Training
Description: Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Bystander Training
Description: In-person training of large groups of 120-150 students; training lasts 3-4 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Combination Training
Description: In-person training of large groups of 120-150 students; training lasts 3-4 hours